At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating gemcitabine hydrochloride, oxaliplatin, and 6 other interventions for Pancreatic Cancer. Completed, enrolled 39 participants across 1 site.
Detailed Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving gemcitabine together with oxaliplatin works in treating patients with pancreatic cancer that can be removed by surgery.
Study Details
Timeline
Interventions
1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.